Enhanced Migraine Treatment System with Improved Efficacy and Patient Personalization

The present inventive concept discloses a novel system for treating migraine, which overcomes the limitations of existing treatments by providing rapid onset of action, improved efficacy, and personalized dosing recommendations for patients with severe renal impairment.

Migraine is a prevalent and debilitating neurological condition with a significant unmet need for effective treatments. The original patent disclosed a method for the acute treatment of migraine with or without aura using ubrogepant, but it had limitations in terms of efficacy and patient personalization. The present inventive concept addresses these limitations by introducing a system that combines a CGRP receptor antagonist with a wearable device that monitors migraine symptoms and provides personalized dosing recommendations.

The inventive concept comprises a system for treating migraine, which includes a CGRP receptor antagonist, such as ubrogepant, formulated to provide a rapid onset of action and improved efficacy in patients with severe renal impairment. The system also includes a wearable device that monitors migraine symptoms and provides personalized dosing recommendations based on the monitored symptoms. Additionally, the system may include a pharmaceutical composition comprising ubrogepant and a cytochrome P450 3A4 inhibitor to reduce the metabolism of ubrogepant and improve its efficacy. The inventive concept also discloses a method for treating acute migraine, comprising orally administering a 50 mg dose of ubrogepant followed by a 25 mg dose 2 hours later, to provide a sustained therapeutic effect.

The present inventive concept is novel and non-obvious over the original patent because it introduces a wearable device that provides personalized dosing recommendations, a pharmaceutical composition that improves the efficacy of ubrogepant, and a method for treating acute migraine with a sustained therapeutic effect. These features overcome the limitations of existing treatments and provide a significant improvement in the treatment of migraine.

Alternative embodiments of the inventive concept may include using different CGRP receptor antagonists, varying the dosage and administration schedule of ubrogepant, and incorporating additional therapeutic agents to enhance the efficacy of the treatment. The wearable device may also be modified to include additional features, such as tracking patient adherence to treatment and providing real-time feedback to healthcare providers.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the treatment of migraine. The market for migraine treatments is growing rapidly, and the present inventive concept is well-positioned to capture a significant share of this market. The inventive concept's ability to provide rapid onset of action, improved efficacy, and personalized dosing recommendations makes it an attractive option for patients and healthcare providers.